Home / Going-concern warnings / Karyopharm Therapeutics Inc.
Filed 2026-08-13 路 Form 10-Q 路 Accession 0001193125-26-347906 micro
Price before filing: $2.03 (2026-08-12 close, split/dividend-adjusted)
Market cap at flag: $57.6M (2026-08-13) 路 Latest: $11.3M (2026-10-16)
| Window | KPTI | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -21.2% | -1.5% | -19.7% | 2026-09-14 |
| 90 days | pending | pending | until 2026-11-11 | |
| 180 days | pending | pending | until 2027-02-09 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding or other strategic alternatives and considering our debt service obligations and financial covenant to maintain minimum liquidity, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date the..."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-06-30)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.